Endogenous modulators of TNF and IL-1 response are under partial control of TNF in baboon bacteremia

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 271, Issue 5 40-5, 1996, Pages

  Redl, H ^a   Schlag, G ^b   Paul, E ^b   Bahrami, S ^b   Buurman, W A ^b   Strieter, R M ^b   Kunkel, S L ^b   Davies, J ^b   Foulkes, R ^b  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b NONE

Author keywords

anti tumor necrosis factor antibody; Escherichia coli bacteremia; humanized; interleukin 1; monocyte chemotactic peptide 1; receptor antagonist; soluble tumor necrosis factor receptor

Indexed keywords

INTERLEUKIN 1; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BABOON; BACTEREMIA; COLONY FORMING UNIT; CONTROL SYSTEM; CONTROLLED STUDY; ENDOTOXEMIA; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SURVIVAL;

EID: 0029853846     PISSN: 03636119     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpregu.1996.271.5.r1193     Document Type: Article

References (43)

1. Bahrami, S., G. Leichtfried, H. Redl, and G. Schlag. A kinetic-chromogenic method to determine endotoxin on microplates. Eur. Clin. Lab. News: 8-9, 1991.
2. Bemelmans, M. H. A., D. J. Gouma, and W. A. Buurman. LPS-induced sTNF-receptor release in vivo in a murine model. Investigation of the role of tumor necrosis factor, IL-1, leukemia inhibiting factor, and IFN-gamma. J. Immunol. 151: 5554-5562, 1993.
3. Bemelmans, M. H. A., D. J. Gouma, and W. A. Buurman. Tissue distribution and clearance of soluble murine TNF receptor in mice. Cytokine 6: 608-615, 1994.
4. Christensen, P. J., M. W. Rolfe, T. J. Standiford, M. D. Burdick, G. B. Toews, and R. M. Strieter. Characterization of the production of monocyte chemoattractant protein-1 and IL-8 in an allogeneic immune response. J. Immunol. 151: 1205-1213, 1993.
5. David, H. A., H. O. Hartley, and E. S. Person. The distribution of the ratio in a single normal sample, of range to standard deviation. Biometrika 41: 482-493, 1954.
6. Eisenberg, S. P., R. J. Evans, W. P. Arend, E. Verderber, M. T. Brewer, C. H. Hannum, and R. C. Thompson. Primary structure and functional expression from complementary DNA of a human interleukin 1 receptor antagonist. Nature Lond. 343: 341-346, 1990.
7. Engelberts, I., S. Stephens, G. J. M. Francot, C. J. Van der Linden, and W. A. Buurman. Evidence of different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 338: 515-516, 1991.
8. Evanoff, H. L., M. D. Burdick, S. A. Moore, S. L. Kunkel, and R. M. Strieter. A sensitive ELISA for the detection of human monocyte chemoattractant protein-1 (MCP-1). Immunol. Invest. 21: 39-45, 1992.
9. Fischer, E., M. A. Marano, A. E. Barber, A. Hudson, K. Lee, C. S. Rock, A. S. Hawes, R. C. Thompson, T. J. Hayes, T. D. Anderson, W. R. Benjamin, S. F. Lowry, and L. L. Moldawer. Comparison between effects of interleukin-1α administration and sublethal endotoxemia in primates. Am. J. Physiol. 261 (Regulatory Integrative Comp. Physiol. 30): R442-R452, 1991.
10. Fischer, E., M. A. Marano, K. J. Van Zee, C. S. Rock, A. S. Hawes, W. A. Thompson, L. Deforge, J. S. Kenney, D. G. Remick, D. C. Bloedow, R. C. Thompson, S. F. Lowry, and L. L. Moldawer. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J. Clin. Invest. 89: 1551-1557, 1992.
11. Fischer, E., K. J. Van Zee, M. A. Marano, C. S. Rock, J. S. Kenney, D. D. Poutsiaka, C. A. Dinarello, S. F. Lowry, and L. L. Moldawer. Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79: 2196-2200, 1992.
12. Fisher, C. J. J., G. J. Slotman, S. M. Opal, J. P. Pribble, R. C. Bone, G. Emmanuel, D. Ng, D. C. Bloedow, M. A. Catalano, and The IL-1ra Sepsis Syndrome Study Group. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. 22: 12-21, 1994.
13. Fong, Y., K. J. Tracey, L. L. Moldawer, D. G. Hesse, K. B. Manogue, J. S. Kenney, A. T. Lee, G. C. Kuo, A. C. Allison, S. Lowry, and A. Cerami. Antibodies to cachectin tumor necrosis factor reduce interleukin 1α and interleukin 6 appearance during lethal bacteremia. J. Exp. Med. 170: 1627-1633, 1989.
14. Frieling, J. T. M., M. van Deuren, J. Wijdenes, J. W. M. van der Meer, C. Clement, C. J. Van der Linden, and R. W. Sauerwein. Circulating interleukin-6 receptor in patients with sepsis syndrome. J. Infect. Dis. 171: 469-472, 1990.
15. Froon, A. H. M., M. H. A. Bemelmans, J. W. Greve, C. J. Van der Linden, and W. A. Buurman. Increased plasma concentrations of soluble tumor necrosis factor receptors in sepsis syndrome: correlation with plasma creatinine values. Crit Care Med. 22: 803-809, 1994.
16. Girardin, E., P. Roux-Lombard, G. E. Grau, P. Suter, H. Gallati, and The J5 Study Group. Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 76: 20-23, 1992.
17. Junger, W. G., D. B. Hoyt, H. Redl, F. C. Liu, W. H. Loomis, J. Davies, and G. Schlag. Tumor necrosis factor antibody treatment of septic baboons reduces the production of sustained T-cell suppressive factors (TSF). Shock 3: 173-178, 1995.
18. Leeuwenberg, J. F. M., M. A. Dentener, and W. A. Buurman. Lipopolysaccharide LPS-mediated soluble TNF receptor release and TNF receptor expression by monocytes. Role of CD14, LPS binding protein, and bactericidal/permeability-increasing protein. J. Immunol. 152: 5070-5076, 1995.
19. Matsushima, K., E. T. Baldwin, and N. Mukaida. Interleukin-8 and MCAF: novel leukocyte recruitment and activating cytokines. In: Interleukins: Molecular Biology and Immunology, edited by T. Kishimoto. Basel: Karger, 1992, p. 236-265.
20. Moore, K. W., A. O'Garra, R. de Waal Malefyt, P. Vieira, and T. R. Mosmann. Interleukin-10. Annu. Rev. Immunol. 11: 165-187, 1993.
21. Ohlsson, K., P. Bjork, M. Bergenfeldt, R. Hageman, and R. C. Thompson. An interleukin-1 receptor antagonist reduces mortality in endotoxin shock. Nature Lond. 348: 550-552, 1990.
22. Okusawa, S., J. A. Gelfand, T. Ikejima, R. J. Connolly, and C. A. Dinarello. Interleukin 1 induces a shock-like state in rabbits. J. Clin. Invest. 81: 1162-1172, 1988.
23. Re, F., M. Mengozzi, M. Muzio, C. A. Dinarello. A. Mantovani, and F. Colotta. Expression of interleukin-1 receptor antagonist (IL-1ra) by human circulating polymorphonuclear cells. Eur. J. Immunol. 23: 570-573, 1993.
24. Redl, H., S. Bahrami, G. Leichtfried, and G. Schlag. Special collection and storage tubes for blood endotoxin and cytokine measurements. Clin. Chem. 38: 764-765, 1992.
25. Redl, H., G. Schlag, S. Bahrami, J. Davies, S. Stevens, R. Foulkes, and M. Bodmer. Influence of TNF antibody treatment on mediator release in baboon bacteremia/endotoxemia. In: Bacterial Endotoxin: Recognition and Effector Mechanisms. Proceedings of the Second Congress of the International Endotoxin Society, Vienna, August 17-20, 1992. edited by J. Leven, C. R. Alving, R. S. Munford, and P. L. Stütz. Amsterdam: Elsevier, 1993, p. 433-441.
26. Redl, H., G. Schlag, S. Bahrami, U. Schade, M. Ceska, and P. Stütz. Plasma neutrophil-activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model. J. Infect. Dis. 164: 383-388, 1991.
27. Redl, H., G. Schlag, M. Ceska, J. Davies, and W. A. Buurman. Interleukin-8 release in baboon septicemia is partially dependent on tumor necrosis factor. J. Infect. Dis. 167: 1464-1466, 1993.
28. Redl, H., G. Schlag, A. Schiesser, and J. Davies. Tumor necrosis factor is a mediator of phospholipase release during bacteremia in baboons. Am. J. Physiol. 264 (Heart Circ. Physiol. 33): H2119-H2123, 1993.
29. Redl, H., G. Schlag, A. Schiesser, and J. Davies. Thrombomodulin release in baboon sepsis: its dependence on the dose of Escherichia coli and the presence of tumor necrosis factor. J. Infect. Dis. 171: 1522-1527, 1995.
30. Rogy, M. A., S. M. Coyle, H. S. A. Oldenburg, C. S. Rock, P. S. Barie, K. J. Van Zee, C. G. Smith, L. L. Moldawer, and S. F. Lowry. Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J. Am. Coll. Surg. 178: 132-138, 1994.
31. Rollins, B. J., T. Yoshimura, E. J. Leonard, and J. S. Pober. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am. J. Pathol. 136: 1229-1233, 1990.
32. Schlag, G., H. Redl, J. Davies, M. W. Bodmer, and R. Foulkes. Humanized TNF-antibodies in a subchronic septic model in baboons with single bacterial challenge to improve survival and to prevent multi-organ failure (MOF). Circ. Shock 37: 52-53, 1992.
33. Schlag, G., H. Redl, J. Davies, and I. Haller. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock 2: 10-18, 1994.
34. Schlag, G., H. Redl, J. Davies, C. J. J. Van Vuuren, and P. Smuts. Live Escherichia coli sepsis model in baboons. In: Pathophysiology of Shock, Sepsis, and Organ Failure, edited by G. Schlag and H. Redl. Berlin: Springer-Verlag, 1993, p. 1076-1107.
35. Schlag, G., H. Redl, Z. Khakpour, J. Davies, and J. Pretorius. Hypovolemic-traumatic shock models in baboons. In: Pathophysiology of Shock, Sepsis, and Organ Failure, edited by G. Schlag and H. Redl. Berlin: Springer-Verlag, 1993, p. 384-402.
36. Spinas, G. A., D. Bloesch, M.-T. Kaufmann, U. Keller, and J.-M. Dayer. Induction of plasma inhibitors of interleukin-1 and TNF-α activity by endotoxin administration to normal humans. Am. J. Physiol. 259 (Regulatory Integrative Comp. Physiol. 28): R993-R997, 1990.
37. Spinas, G. A., U. Keller, and M. Brockhaus. Release of soluble receptors for tumor necrosis factor (TNF) in relation to circulating TNF during experimental endotoxinemia. J. Clin. Invest. 90: 533-536, 1992.
38. Steinshamn, S., M. H. A. Bemelmans, W. A. Buurman, and A. Waage. Granulocytopenia reduces release of soluble TNF receptor p75 in endotoxin-stimulated mice: a possible mechanism of enhanced TNF activity. Cytokine 7: 50-56, 1995.
39. Tracey, K. J., Y. Fong, D. G. Hesse, K. R. Manogue, A. T. Lee, G. C. Kuo, S. F. Lowry, and A. Cerami. Anti cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia. Nature Lond. 330: 62-664, 1987.
40. Van der Poll, T., J. Jansen, M. Levi, H. Ten Cate, J. W. Ten Cate, and S. J. H. van Deventer. Regulation of interleukin 10 release by tumor necrosis factor in humans and chimpanzees. J. Exp. Med. 180: 1985-1988, 1994.
41. Van der Poll, T., M. Levi, S. J. Van Deventer, H. Ten Cate, B. L. Haagmans, B. J. Biemond, H. R. Büller, C. E. Hack, and J. W. Ten Cate. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 83: 446-451, 1994.
42. Waage, A. and T. Espevik. Interleukin-1 potentiates the lethal effect of tumor necrosis factor alpha/cachectin in mice. J. Exp. Med. 167: 1987-1992, 1992.
43. Wakabayashi, G., J. A. Gelfand, J. F. Burke, and C. A. Dinarello. A specific receptor antagonist for interleukin-1 prevents E. coli-induced septic shock in rabbits. FASEB J. 5: 338-343, 1991.